Radiolabelled Oligonucleotides(Aptamer, siRNA, ASO, microRNA)

Radiolabelled Oligonucleotides(Aptamer, siRNA, ASO, microRNA)

At present, PET with high sensitivity and high spatial resolution is a leading technology in the field of molecular imaging. PET combined with probes that can specifically bind to molecular targets can qualitatively and quantitatively study the process of tumor occurrence and development at the cellular and molecular levels in vivo, non invasively, repetitively, and in real time. Aptamers have strong affinity at lower concentrations and can undergo various chemical modifications and labeling. Therefore, the use of radiolabeled highly specific nucleic acid aptamer probes has unique advantages in tumor diagnosis.

In addition, the application of siRNA in vivo also faces some urgent problems, such as off target effects of siRNA therapy in vivo, non-specific transport distribution, and potential risks of activating immune responses. The in vivo distribution of siRNA is crucial for the effectiveness of RNAi technology in vivo, therefore, the development of appropriate methods for evaluating the in vivo distribution of siRNA is receiving increasing attention. The methods used to evaluate in vivo distribution include invasive measurement and non-invasive imaging. Invasive measurement refers to evaluating the distribution of probes by measuring the concentration of probes in isolated organs after euthanizing experimental animals. Non invasive imaging techniques mainly include radionuclide imaging, fluorescence imaging, and optical imaging, which provide feasibility for non-invasive tracking of siRNA in vivo. Radioisotope tracing, as a widely used imaging technique in clinical and scientific research, has the characteristics of non invasiveness, high sensitivity, and strong specificity. Compared with fluorescence and optical imaging techniques, radionuclide imaging is non-toxic and highly safe, especially suitable for imaging large animals and even humans. The application of radioactive tracing technology in siRNA in vivo imaging provides technical support for future siRNA based radionuclide therapy, which can provide intuitive imaging evaluation of treatment effects and achieve dual therapeutic effects of RNAi gene therapy and radiation therapy, which is conducive to promoting the development of RNAi technology in vivo applications. Biosyntech can provide chelating agent modified oligonucleotide products (NOTA, DOTA, MAG, HYNIC, DTPA, TETA, etc.), which can be used for radiolabeling. The characteristics of commonly used radioactive nuclides and strategies for radiolabeling oligonucleotides are as follows:

List of aptamers that have been radiolabeled for diagnostic or therapeutic applications